Aligos' HBV Drug Pevifoscorvir Sodium Gains FDA Fast Track as Phase 2 Study Expands
Event summary
- Aligos Therapeutics' Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic HBV patients will increase sample size to 100 in the HBeAg- cohort after DSMB recommendation.
- FDA granted Fast Track Designation to pevifoscorvir sodium, citing unmet medical need in chronic HBV treatment.
- Study drugs were well-tolerated with no clinically concerning safety signals observed.
- Topline data from the study remains on track for 2027, with completion of enrollment expected in the second half of 2026.
The big picture
Aligos' progress with pevifoscorvir sodium comes as chronic HBV remains a significant global health burden with limited curative options. The Fast Track Designation underscores the urgency in developing new therapies for this indication, potentially positioning Aligos as a key player in the HBV treatment landscape. The expanded study cohort reflects growing confidence in the drug's potential, though execution risks remain as the company navigates the competitive landscape of antiviral development.
What we're watching
- Regulatory Advantage
- How FDA Fast Track Designation will accelerate pevifoscorvir sodium's development timeline and potential approval path.
- Clinical Execution
- Whether Aligos can successfully enroll the additional 26 participants in the HBeAg- cohort by the second half of 2026.
- Competitive Positioning
- The pace at which pevifoscorvir sodium can demonstrate superior efficacy compared to existing HBV treatments.
Related topics